Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

10 Jul 2015 16:34

Tate & Lyle PLC

Director/PDMR Shareholding

Tate & Lyle PLC (the “Company”) has been informed that today William Camp, a Non-Executive Director of the Company, acquired an interest in 2,000 ordinary 25p shares in the capital of the Company (“Shares”) by means of the purchase of 500 American Depositary Receipts (“ADRs”) (one ADR being equivalent to four Shares) on the New York Stock Exchange at a price of 522.96 pence per share (being the equivalent of US$32.43 per ADR using an exchange rate of 1.5503). Mr Camp now has an interest in 6,800 Shares in the Company.

This notification is made in accordance with DTR 3.1.4R(1)(a) of the FCA’s Disclosure and Transparency Rules.

Lucie Gilbert

Company Secretary

10 July 2015

View source version on businesswire.com: http://www.businesswire.com/news/home/20150710005534/en/

Copyright Business Wire 2015

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.